View Past PerformanceTalea Group バランスシートの健全性財務の健全性 基準チェック /36Talea Groupの総株主資本は€34.7M 、総負債は€0.0で、負債比率は0%となります。総資産と総負債はそれぞれ€142.0Mと€107.3Mです。主要情報0%負債資本比率€0負債インタレスト・カバレッジ・レシオn/a現金€8.21mエクイティ€34.71m負債合計€107.33m総資産€142.04m財務の健全性に関する最新情報分析記事 • Apr 20Is Talea Group (BIT:TALEA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 14Is Talea Group (BIT:TALEA) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 11These 4 Measures Indicate That Farmaè (BIT:FAR) Is Using Debt ExtensivelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • May 30Farmaè (BIT:FAR) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...すべての更新を表示Recent updatesBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Director Marco Guidi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Feb 28New major risk - Revenue and earnings growthRevenue has declined by 4.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 4.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€40.7m market cap, or US$48.2m).New Risk • Jan 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€40.7m market cap, or US$47.3m).Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Marco Guidi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Oct 27Price target decreased by 7.0% to €10.60Down from €11.40, the current price target is provided by 1 analyst. New target price is 121% above last closing price of €4.80. Stock is down 7.3% over the past year. The company posted a net loss per share of €0.39 last year.分析記事 • Jun 20Talea Group S.p.A. (BIT:TALEA) Shares Slammed 27% But Getting In Cheap Might Be Difficult RegardlessThe Talea Group S.p.A. ( BIT:TALEA ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • May 04Talea Group S.p.A. (BIT:TALEA) Stocks Shoot Up 31% But Its P/S Still Looks ReasonableTalea Group S.p.A. ( BIT:TALEA ) shareholders would be excited to see that the share price has had a great month...Price Target Changed • Apr 25Price target decreased by 11% to €10.60Down from €11.90, the current price target is provided by 1 analyst. New target price is 123% above last closing price of €4.75. Stock is down 22% over the past year.New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (€35.6m market cap, or US$40.4m).New Risk • Feb 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (€43.3m market cap, or US$45.2m).分析記事 • Feb 10Investors Continue Waiting On Sidelines For Talea Group S.p.A. (BIT:TALEA)There wouldn't be many who think Talea Group S.p.A.'s ( BIT:TALEA ) price-to-sales (or "P/S") ratio of 0.3x is worth a...Price Target Changed • Nov 13Price target decreased by 10% to €10.70Down from €11.90, the current price target is an average from 2 analysts. New target price is 138% above last closing price of €4.50. Stock is down 47% over the past year. The company is forecast to post a net loss per share of €0.25 next year compared to a net loss per share of €1.10 last year.分析記事 • Oct 27Market Still Lacking Some Conviction On Talea Group S.p.A. (BIT:TALEA)With a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Italy, you could...分析記事 • Jun 12Talea Group S.p.A. (BIT:TALEA) Could Be Riskier Than It LooksWith a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Italy, you could...分析記事 • Apr 20Is Talea Group (BIT:TALEA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Mar 29+ 2 more updatesTalea Group S.p.A., Annual General Meeting, Apr 29, 2024Talea Group S.p.A., Annual General Meeting, Apr 29, 2024.New Risk • Mar 11New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 61% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Share price has been volatile over the past 3 months (5.8% average weekly change). Market cap is less than US$100m (€46.4m market cap, or US$50.7m).分析記事 • Feb 07Talea Group S.p.A. (BIT:TALEA) Screens Well But There Might Be A CatchThere wouldn't be many who think Talea Group S.p.A.'s ( BIT:TALEA ) price-to-sales (or "P/S") ratio of 0.4x is worth a...Price Target Changed • Oct 11Price target decreased by 11% to €15.15Down from €17.00, the current price target is an average from 2 analysts. New target price is 61% above last closing price of €9.40. Stock is down 1.1% over the past year. The company is forecast to post a net loss per share of €0.15 next year compared to a net loss per share of €0.14 last year.Buying Opportunity • Oct 10Now 22% undervaluedOver the last 90 days, the stock is up 2.3%. The fair value is estimated to be €12.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company became loss making.分析記事 • Jun 14Is Talea Group (BIT:TALEA) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Buying Opportunity • May 24Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €14.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 5.5%. Revenue is forecast to grow by 27% in a year. Earnings is forecast to grow by 89% in the next year.Buying Opportunity • May 09Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be €14.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 5.5%. Revenue is forecast to grow by 27% in a year. Earnings is forecast to grow by 89% in the next year.Price Target Changed • May 07Price target increased by 15% to €19.50Up from €17.00, the current price target is provided by 1 analyst. New target price is 68% above last closing price of €11.60. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.009 next year compared to a net loss per share of €0.14 last year.Reported Earnings • Apr 19Full year 2022 earnings released: €0.14 loss per share (vs €0.013 loss in FY 2021)Full year 2022 results: €0.14 loss per share (further deteriorated from €0.013 loss in FY 2021). Revenue: €116.3m (up 41% from FY 2021). Net loss: €948.9k (loss widened €859.2k from FY 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.Price Target Changed • Nov 16Price target decreased to €15.50Down from €25.00, the current price target is an average from 2 analysts. New target price is 35% above last closing price of €11.50. Stock is down 65% over the past year. The company is forecast to post earnings per share of €0.047 next year compared to a net loss per share of €0.013 last year.Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Marco Guidi was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.分析記事 • Nov 03Calculating The Fair Value Of Farmaè S.p.A. (BIT:FAR)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Farmaè S.p.A...Buying Opportunity • Oct 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be €11.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 58% in 2 years. Earnings is forecast to grow by 2,339% in the next 2 years.Reported Earnings • Sep 28First half 2022 earnings released: EPS: €0 (vs €0.023 loss in 1H 2021)First half 2022 results: EPS: €0 (improved from €0.023 loss in 1H 2021). Revenue: €52.8m (up 32% from 1H 2021). Net income: €403.8k (up €533.7k from 1H 2021). Profit margin: 0.8% (up from net loss in 1H 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Consumer Retailing industry in Europe.Buying Opportunity • Aug 23Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.4%. The fair value is estimated to be €15.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Meanwhile, the company became loss making.分析記事 • Jun 11These 4 Measures Indicate That Farmaè (BIT:FAR) Is Using Debt ExtensivelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Director Marco Guidi was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 19Full year 2021 earnings released: €0.013 loss per share (vs €0.17 loss in FY 2020)Full year 2021 results: €0.013 loss per share (up from €0.17 loss in FY 2020). Revenue: €82.5m (up 29% from FY 2020). Net loss: €89.7k (loss narrowed 91% from FY 2020).お知らせ • Mar 01Farmaè S.p.A. to Report Fiscal Year 2021 Results on Mar 30, 2022Farmaè S.p.A. announced that they will report fiscal year 2021 results on Mar 30, 2022Reported Earnings • Sep 29First half 2021 earnings releasedThe company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €40.1m (up 27% from 1H 2020). Net loss: €129.9k (loss narrowed 56% from 1H 2020).Reported Earnings • Jul 08Full year 2020 earnings released: €0.096 loss per share (vs €0.011 loss in FY 2019)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €65.5m (up 75% from FY 2019). Net loss: €548.3k (loss widened €484.6k from FY 2019).お知らせ • Jun 30Farmaè S.p.A. (BIT:FAR) agreed to acquire AmicaFarmacia S.r.l. from Marco Di Filippo for €39.6 million.Farmaè S.p.A. (BIT:FAR) signed a binding framework agreement to acquire AmicaFarmacia S.r.l. from Marco Di Filippo for €39.6 million on June 29, 2021. The transaction entails the partial demerger of the AmicaFarmacia assets through the assignment of the business unit dedicated to the online marketing of cosmetics, over-the-counter drugs, supplements, baby products and other products sold through the website, including the parapharmacy located in Bagnolo Piemonte instrumental for online marketing to MDF Holding S.r.l., wholly owned by Marco Di Filippo. Following the completion of the Demerger, Farmaè will acquire from Marco Di Filippo 100% of the capital of AmicaFarmacia; and will approve a capital increase in favour of MDF Holding. The capital increase provides for the issue of approximately 1.1 million ordinary shares of Farmaè at a price of €28.77 for a total value of €32 million. For December 31, 2021, AmicaFarmacia had revenues of €27.8 million, and EBITDA of €0.03 million. On the date of completion, a shareholders' agreement will be entered into by Riccardo Iacometti, Marco Di Filippo and MDF Holding, which provides for, inter alia, Riccardo Iacometti's commitment to include Marco Di Filippo in his list of candidates for the position of Director of Farmaè. Under the terms of the shareholders' agreement, the AmicaFarmacia Board of Directors will be composed of three members, two of whom (including the Chairman) will be appointed by Farmaè and one by Marco Di Filippo. Marco Di Filippo will be the Chief Executive Officer of AmicaFarmacia and he will be assigned the duties and will be vested with the related powers as provided for in the administration agreement that will be entered into by Marco Di Filippo, Farmaè and AmicaFarmacia on the date of completion of the transaction. This agreement also provides that Marco Di Filippo, as Director of Farmaè, will be assigned the role of General Manager of the business unit linked to the brand "AmicaFarmacia", furthermore Marco Di Filippo will be a Member of the Steering Committee and of the Strategic/Operational Committee of Farmaè. The transaction is subject to the occurrence of certain conditions precedent, including the completion of the demerger and the non-occurrence of an event prejudicial to the transaction. The transaction is expected to complete in the second half of September 2021. Stefano Bellavita, Alfio Alessi, and Valentina Perrone of Alantra Capital Markets acted as financial advisors; Alessandro Marena and Francesca Leverone of Pedersoli Law Firm acted as legal advisors; and Davide Bertoia, Gabriele Arioli, Paolo Cornago, Marco Manfredi, and Giorgio Orlandini of Deloitte acted as accountants to Farmaè S.p.A. Gerardo Gabrielli of Gattai Minoli & Partners law firm; and Giorgio Rabbia of Studio Sismondi-Galvagno and Associati Dottori Commercialisti s.s. acted as legal advisors to Marco Di Filippo and MDF Holding. Filippo Zabban of Studio ZNR Notai acted as the notary public on the transaction.分析記事 • May 30Farmaè (BIT:FAR) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 02Farmaè's (BIT:FAR) Returns On Capital Not Reflecting Well On The BusinessIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €65.5m (up 75% from FY 2019). Net loss: €548.3k (loss widened €484.6k from FY 2019).分析記事 • Feb 17What Kind Of Investors Own Most Of Farmaè S.p.A. (BIT:FAR)?The big shareholder groups in Farmaè S.p.A. ( BIT:FAR ) have power over the company. Institutions often own shares in...Is New 90 Day High Low • Feb 06New 90-day high: €29.50The company is up 86% from its price of €15.90 on 06 November 2020. The Italian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 6.0% over the same period.Is New 90 Day High Low • Jan 11New 90-day high: €15.95The company is up 6.0% from its price of €15.10 on 13 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 5.0% over the same period.分析記事 • Dec 24Farmaè (BIT:FAR) Shareholders Booked A 76% Gain In The Last YearPassive investing in index funds can generate returns that roughly match the overall market. But you can significantly...分析記事 • Nov 19Here's What Farmaè S.p.A.'s (BIT:FAR) Shareholder Ownership Structure Looks LikeIf you want to know who really controls Farmaè S.p.A. (BIT:FAR), then you'll have to look at the makeup of its share...Is New 90 Day High Low • Oct 22New 90-day high: €15.70The company is up 60% from its price of €9.80 on 24 July 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.お知らせ • Sep 25Farmaè S.p.A. to Report Q3, 2020 Results on Oct 13, 2020Farmaè S.p.A. announced that they will report Q3, 2020 results on Oct 13, 2020お知らせ • Aug 29Farmaè S.p.A. to Report First Half, 2020 Results on Sep 25, 2020Farmaè S.p.A. announced that they will report first half, 2020 results on Sep 25, 2020お知らせ • Jul 30Farmaè S.p.A. (BIT:FAR) acquired Valnan S.R.L. for €1.2 million.Farmaè S.p.A. (BIT:FAR) acquired Valnan S.R.L. for €1.2 million on April 23, 2020. Farmaè S.p.A. (BIT:FAR) completed the acquisition of Valnan S.R.L. on April 23, 2020.財務状況分析短期負債: TALEAの 短期資産 ( €58.6M ) は 短期負債 ( €83.0M ) をカバーしていません。長期負債: TALEAの短期資産 ( €58.6M ) が 長期負債 ( €24.3M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: TALEAは負債がありません。負債の削減: TALEA負債比率が34.9%であった 5 年前と比べて負債がありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 TALEAに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。キャッシュランウェイの予測: TALEAの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。健全な企業の発掘7D1Y7D1Y7D1YConsumer-retailing 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 13:11終値2026/05/22 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Talea Group S.p.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Mattia PetraccaIntegrae SPADaniele AlibrandiStifel, Equities Research
分析記事 • Apr 20Is Talea Group (BIT:TALEA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jun 14Is Talea Group (BIT:TALEA) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jun 11These 4 Measures Indicate That Farmaè (BIT:FAR) Is Using Debt ExtensivelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • May 30Farmaè (BIT:FAR) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Director Marco Guidi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Feb 28New major risk - Revenue and earnings growthRevenue has declined by 4.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 4.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€40.7m market cap, or US$48.2m).
New Risk • Jan 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€40.7m market cap, or US$47.3m).
Board Change • Oct 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Marco Guidi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Oct 27Price target decreased by 7.0% to €10.60Down from €11.40, the current price target is provided by 1 analyst. New target price is 121% above last closing price of €4.80. Stock is down 7.3% over the past year. The company posted a net loss per share of €0.39 last year.
分析記事 • Jun 20Talea Group S.p.A. (BIT:TALEA) Shares Slammed 27% But Getting In Cheap Might Be Difficult RegardlessThe Talea Group S.p.A. ( BIT:TALEA ) share price has fared very poorly over the last month, falling by a substantial...
分析記事 • May 04Talea Group S.p.A. (BIT:TALEA) Stocks Shoot Up 31% But Its P/S Still Looks ReasonableTalea Group S.p.A. ( BIT:TALEA ) shareholders would be excited to see that the share price has had a great month...
Price Target Changed • Apr 25Price target decreased by 11% to €10.60Down from €11.90, the current price target is provided by 1 analyst. New target price is 123% above last closing price of €4.75. Stock is down 22% over the past year.
New Risk • Apr 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (€35.6m market cap, or US$40.4m).
New Risk • Feb 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (€43.3m market cap, or US$45.2m).
分析記事 • Feb 10Investors Continue Waiting On Sidelines For Talea Group S.p.A. (BIT:TALEA)There wouldn't be many who think Talea Group S.p.A.'s ( BIT:TALEA ) price-to-sales (or "P/S") ratio of 0.3x is worth a...
Price Target Changed • Nov 13Price target decreased by 10% to €10.70Down from €11.90, the current price target is an average from 2 analysts. New target price is 138% above last closing price of €4.50. Stock is down 47% over the past year. The company is forecast to post a net loss per share of €0.25 next year compared to a net loss per share of €1.10 last year.
分析記事 • Oct 27Market Still Lacking Some Conviction On Talea Group S.p.A. (BIT:TALEA)With a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Italy, you could...
分析記事 • Jun 12Talea Group S.p.A. (BIT:TALEA) Could Be Riskier Than It LooksWith a median price-to-sales (or "P/S") ratio of close to 0.4x in the Consumer Retailing industry in Italy, you could...
分析記事 • Apr 20Is Talea Group (BIT:TALEA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Mar 29+ 2 more updatesTalea Group S.p.A., Annual General Meeting, Apr 29, 2024Talea Group S.p.A., Annual General Meeting, Apr 29, 2024.
New Risk • Mar 11New major risk - Revenue and earnings growthEarnings have declined by 61% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 61% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-€11m). Share price has been volatile over the past 3 months (5.8% average weekly change). Market cap is less than US$100m (€46.4m market cap, or US$50.7m).
分析記事 • Feb 07Talea Group S.p.A. (BIT:TALEA) Screens Well But There Might Be A CatchThere wouldn't be many who think Talea Group S.p.A.'s ( BIT:TALEA ) price-to-sales (or "P/S") ratio of 0.4x is worth a...
Price Target Changed • Oct 11Price target decreased by 11% to €15.15Down from €17.00, the current price target is an average from 2 analysts. New target price is 61% above last closing price of €9.40. Stock is down 1.1% over the past year. The company is forecast to post a net loss per share of €0.15 next year compared to a net loss per share of €0.14 last year.
Buying Opportunity • Oct 10Now 22% undervaluedOver the last 90 days, the stock is up 2.3%. The fair value is estimated to be €12.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 31% over the last 3 years. Meanwhile, the company became loss making.
分析記事 • Jun 14Is Talea Group (BIT:TALEA) Using Debt Sensibly?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Buying Opportunity • May 24Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 19%. The fair value is estimated to be €14.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 5.5%. Revenue is forecast to grow by 27% in a year. Earnings is forecast to grow by 89% in the next year.
Buying Opportunity • May 09Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 13%. The fair value is estimated to be €14.11, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 33% over the last 3 years. Earnings per share has grown by 5.5%. Revenue is forecast to grow by 27% in a year. Earnings is forecast to grow by 89% in the next year.
Price Target Changed • May 07Price target increased by 15% to €19.50Up from €17.00, the current price target is provided by 1 analyst. New target price is 68% above last closing price of €11.60. Stock is down 17% over the past year. The company is forecast to post a net loss per share of €0.009 next year compared to a net loss per share of €0.14 last year.
Reported Earnings • Apr 19Full year 2022 earnings released: €0.14 loss per share (vs €0.013 loss in FY 2021)Full year 2022 results: €0.14 loss per share (further deteriorated from €0.013 loss in FY 2021). Revenue: €116.3m (up 41% from FY 2021). Net loss: €948.9k (loss widened €859.2k from FY 2021). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.
Price Target Changed • Nov 16Price target decreased to €15.50Down from €25.00, the current price target is an average from 2 analysts. New target price is 35% above last closing price of €11.50. Stock is down 65% over the past year. The company is forecast to post earnings per share of €0.047 next year compared to a net loss per share of €0.013 last year.
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director Marco Guidi was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
分析記事 • Nov 03Calculating The Fair Value Of Farmaè S.p.A. (BIT:FAR)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Farmaè S.p.A...
Buying Opportunity • Oct 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be €11.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 58% in 2 years. Earnings is forecast to grow by 2,339% in the next 2 years.
Reported Earnings • Sep 28First half 2022 earnings released: EPS: €0 (vs €0.023 loss in 1H 2021)First half 2022 results: EPS: €0 (improved from €0.023 loss in 1H 2021). Revenue: €52.8m (up 32% from 1H 2021). Net income: €403.8k (up €533.7k from 1H 2021). Profit margin: 0.8% (up from net loss in 1H 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Consumer Retailing industry in Europe.
Buying Opportunity • Aug 23Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.4%. The fair value is estimated to be €15.03, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Meanwhile, the company became loss making.
分析記事 • Jun 11These 4 Measures Indicate That Farmaè (BIT:FAR) Is Using Debt ExtensivelyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 6 non-independent directors. Director Marco Guidi was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 19Full year 2021 earnings released: €0.013 loss per share (vs €0.17 loss in FY 2020)Full year 2021 results: €0.013 loss per share (up from €0.17 loss in FY 2020). Revenue: €82.5m (up 29% from FY 2020). Net loss: €89.7k (loss narrowed 91% from FY 2020).
お知らせ • Mar 01Farmaè S.p.A. to Report Fiscal Year 2021 Results on Mar 30, 2022Farmaè S.p.A. announced that they will report fiscal year 2021 results on Mar 30, 2022
Reported Earnings • Sep 29First half 2021 earnings releasedThe company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €40.1m (up 27% from 1H 2020). Net loss: €129.9k (loss narrowed 56% from 1H 2020).
Reported Earnings • Jul 08Full year 2020 earnings released: €0.096 loss per share (vs €0.011 loss in FY 2019)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €65.5m (up 75% from FY 2019). Net loss: €548.3k (loss widened €484.6k from FY 2019).
お知らせ • Jun 30Farmaè S.p.A. (BIT:FAR) agreed to acquire AmicaFarmacia S.r.l. from Marco Di Filippo for €39.6 million.Farmaè S.p.A. (BIT:FAR) signed a binding framework agreement to acquire AmicaFarmacia S.r.l. from Marco Di Filippo for €39.6 million on June 29, 2021. The transaction entails the partial demerger of the AmicaFarmacia assets through the assignment of the business unit dedicated to the online marketing of cosmetics, over-the-counter drugs, supplements, baby products and other products sold through the website, including the parapharmacy located in Bagnolo Piemonte instrumental for online marketing to MDF Holding S.r.l., wholly owned by Marco Di Filippo. Following the completion of the Demerger, Farmaè will acquire from Marco Di Filippo 100% of the capital of AmicaFarmacia; and will approve a capital increase in favour of MDF Holding. The capital increase provides for the issue of approximately 1.1 million ordinary shares of Farmaè at a price of €28.77 for a total value of €32 million. For December 31, 2021, AmicaFarmacia had revenues of €27.8 million, and EBITDA of €0.03 million. On the date of completion, a shareholders' agreement will be entered into by Riccardo Iacometti, Marco Di Filippo and MDF Holding, which provides for, inter alia, Riccardo Iacometti's commitment to include Marco Di Filippo in his list of candidates for the position of Director of Farmaè. Under the terms of the shareholders' agreement, the AmicaFarmacia Board of Directors will be composed of three members, two of whom (including the Chairman) will be appointed by Farmaè and one by Marco Di Filippo. Marco Di Filippo will be the Chief Executive Officer of AmicaFarmacia and he will be assigned the duties and will be vested with the related powers as provided for in the administration agreement that will be entered into by Marco Di Filippo, Farmaè and AmicaFarmacia on the date of completion of the transaction. This agreement also provides that Marco Di Filippo, as Director of Farmaè, will be assigned the role of General Manager of the business unit linked to the brand "AmicaFarmacia", furthermore Marco Di Filippo will be a Member of the Steering Committee and of the Strategic/Operational Committee of Farmaè. The transaction is subject to the occurrence of certain conditions precedent, including the completion of the demerger and the non-occurrence of an event prejudicial to the transaction. The transaction is expected to complete in the second half of September 2021. Stefano Bellavita, Alfio Alessi, and Valentina Perrone of Alantra Capital Markets acted as financial advisors; Alessandro Marena and Francesca Leverone of Pedersoli Law Firm acted as legal advisors; and Davide Bertoia, Gabriele Arioli, Paolo Cornago, Marco Manfredi, and Giorgio Orlandini of Deloitte acted as accountants to Farmaè S.p.A. Gerardo Gabrielli of Gattai Minoli & Partners law firm; and Giorgio Rabbia of Studio Sismondi-Galvagno and Associati Dottori Commercialisti s.s. acted as legal advisors to Marco Di Filippo and MDF Holding. Filippo Zabban of Studio ZNR Notai acted as the notary public on the transaction.
分析記事 • May 30Farmaè (BIT:FAR) Has A Pretty Healthy Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • May 02Farmaè's (BIT:FAR) Returns On Capital Not Reflecting Well On The BusinessIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €65.5m (up 75% from FY 2019). Net loss: €548.3k (loss widened €484.6k from FY 2019).
分析記事 • Feb 17What Kind Of Investors Own Most Of Farmaè S.p.A. (BIT:FAR)?The big shareholder groups in Farmaè S.p.A. ( BIT:FAR ) have power over the company. Institutions often own shares in...
Is New 90 Day High Low • Feb 06New 90-day high: €29.50The company is up 86% from its price of €15.90 on 06 November 2020. The Italian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Jan 11New 90-day high: €15.95The company is up 6.0% from its price of €15.10 on 13 October 2020. The Italian market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is up 5.0% over the same period.
分析記事 • Dec 24Farmaè (BIT:FAR) Shareholders Booked A 76% Gain In The Last YearPassive investing in index funds can generate returns that roughly match the overall market. But you can significantly...
分析記事 • Nov 19Here's What Farmaè S.p.A.'s (BIT:FAR) Shareholder Ownership Structure Looks LikeIf you want to know who really controls Farmaè S.p.A. (BIT:FAR), then you'll have to look at the makeup of its share...
Is New 90 Day High Low • Oct 22New 90-day high: €15.70The company is up 60% from its price of €9.80 on 24 July 2020. The Italian market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is up 2.0% over the same period.
お知らせ • Sep 25Farmaè S.p.A. to Report Q3, 2020 Results on Oct 13, 2020Farmaè S.p.A. announced that they will report Q3, 2020 results on Oct 13, 2020
お知らせ • Aug 29Farmaè S.p.A. to Report First Half, 2020 Results on Sep 25, 2020Farmaè S.p.A. announced that they will report first half, 2020 results on Sep 25, 2020
お知らせ • Jul 30Farmaè S.p.A. (BIT:FAR) acquired Valnan S.R.L. for €1.2 million.Farmaè S.p.A. (BIT:FAR) acquired Valnan S.R.L. for €1.2 million on April 23, 2020. Farmaè S.p.A. (BIT:FAR) completed the acquisition of Valnan S.R.L. on April 23, 2020.